Q1 2024 Travere Therapeutics Inc Earnings Call Transcript
Key Points
- Travere Therapeutics Inc (TVTX) reported a strong start to 2024 with significant progress in key areas, including the commercial launch of their product, which continues to reach new highs.
- The company achieved a 35% growth in revenue over the last quarter, demonstrating robust demand and effective execution by the commercial team.
- Travere Therapeutics Inc (TVTX) successfully received priority review from the FDA for their submission, marking a critical step towards full approval of their product.
- The company has initiated the Phase three HARMONY study and has already dosed the first patients, staying on track with their development timeline.
- Travere Therapeutics Inc (TVTX) has seen an increase in both the breadth and depth of prescribers, indicating growing acceptance and demand for their product in the medical community.
- Despite overall growth, Travere Therapeutics Inc (TVTX) faces typical New Year headwinds with gross-to-net adjustments, which could impact financial performance.
- The company reported a net loss of $136.1 million for the first quarter of 2024, indicating ongoing challenges in achieving profitability.
- Travere Therapeutics Inc (TVTX) is still in the process of transitioning to full approval in Europe, which requires careful management and could pose regulatory challenges.
- There are competitive pressures from other companies developing treatments for similar conditions, which could impact Travere Therapeutics Inc (TVTX)'s market share and growth potential.
- The company anticipates the need for ongoing engagement with the FDA regarding the REMS for liver monitoring, which could lead to additional regulatory hurdles.
Good day, and welcome to the Trevena Therapeutics First Quarter 2024 financial results and corporate update conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to the Manager of Investor Relations, Anne Crotteau. Please go ahead, Anne.
Thank you, Rachel. Good afternoon, and welcome to Trevi Therapeutics First Quarter 2024 financial results and corporate update call.
Thank you all for joining today's call will be led by our President and Chief Executive Officer, Dr. Eric Dube. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, Senior Vice President of Research and Development will join us for the Q&A session.
Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
